• LinkedIn
  • Twitter
Vesigen Therapeutics
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact
  • Menu Menu
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Expanding the universe of druggable targets

Novel Therapeutics Enabled by Engineering ARRDC1-Mediated Microvesicles

Novel technology, new treatment opportunities

Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads, including gene editing complexes, proteins, and RNAs to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet needs.

Learn more about us

Repurposing inter-tissue communication to develop new therapies

ARMMs are a natural communication system used by cells to transfer signals. Vesigen has developed approaches to engineer ARMMs to relay therapeutic payloads to target cells while avoiding endosomal/lysosomal processing and degradation, and to take full advantage of the properties of human extracellular vesicles, such as low immunogenicity and toxicity.

Explore our science

Join a team that’s creating transformative therapeutics

Powered by our breakthrough in engineering ARMMs technology, Vesigen will deliver tomorrow’s precision medicines. If you’re looking for a career opportunity with truly innovative science and potential to transform patient lives, you’re in the right place.

See current opportunities

  • About
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139

LinkeInTwitter

© 2020 Vesigen Therapeutics
All rights reserved.
Privacy Policy
Terms of Use

Design and development by RainCastle Communications
Scroll to top
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact